NF-κΒ activator 1
Based on 13 publication(s) in Google Scholar
NF-κΒ activator 1 (compound 32) is a potent NF-κΒ activator with an EC50 of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD)2 mRNA expression.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 2387524-59-4
- Formula: C16H11FN2O2S
- Molecular Weight:314.33
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Pain-Related Compound Library
HY-L139
-
Highly Selective Activators Library
HY-L159
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) NF-κΒ activator 1
More- J Clin Invest. 2024 Oct 1;134(22):e178628. [Abstract]
- Chem Eng J. 2024 May 1, 487, 150501.
- Carbohydr Polym. 2024 Oct 15:342:122422. [Abstract]
- Cell Death Dis. 2023 Nov 15;14(11):743. [Abstract]
- Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]
- J Mol Cell Cardiol. 2025 May:202:133-143. [Abstract]
- Clin Exp Immunol. 2025 Jan 21;219(1):uxaf055. [Abstract]
- J Immunol. 2025 Jun 28:vkaf125. [Abstract]
- Anim Reprod Sci. 2026 Jun:289:108144. [Abstract]
- Int J Med Sci. 2026 Feb 18;23(3):1092-1104. [Abstract]
- J Cancer. 2025 Jan 1;16(3):1008-1019. [Abstract]
- Behav Brain Res. 2024 Mar 12:461:114837. [Abstract]
- Thromb J. 2025 May 20;23(1):51. [Abstract]
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
WB
-
RT-PCR
Biological Activity
|
NF-κB 0.9 μM (EC50) |
Chemical Information
-
CAS No. 2387524-59-4
-
Appearance Solid
-
Molecular Weight 314.33
-
Formula C16H11FN2O2S
-
Color Light yellow to yellow
-
SMILES
O=C(O)C1=CC=CC(C2=CSC(NC3=CC=CC=C3F)=N2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
J Clin Invest
Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. [Abstract]2024 Oct 1;134(22):e178628. PMID: 39352749 -
-
Carbohydr Polym
A novel strategy with in vivo characterization, extraction, isolation and activity evaluation for discovery of absorbed anti-inflammatory oligosaccharides from Zhu-Ling decoction. [Abstract]2024 Oct 15:342:122422. PMID: 39048245 -
Cell Death Dis
BRISC is required for optimal activation of NF-κB in Kupffer cells induced by LPS and contributes to acute liver injury. [Abstract]2023 Nov 15;14(11):743. PMID: 37968261
NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Nov 15;14(11):743. [Abstract]
WT and Abro1 KCs cells were pretreated with NF-κB activator 1 for 6 hours, followed by treatment with 100 ng/ml LPS for 3 hours. CBA analysis was used to analyze the expression of TNF-α and IL-6.
-
Oncogene
Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-κB activation and promotes docetaxel efficacy in prostate cancer. [Abstract]2024 Sep;43(38):2835-2849. PMID: 39155296
NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]
NF-κΒ activator 1 (1 μM for 48 h). Immunoblot detection of NF-κB p105/50, NF-κB p100, IκBα, Phospho-IκBα (Ser32/36), NF-κB p65 and phospho-NF-κB p65 (Ser536) in Over-MGLL and Vector PC3 cells.
NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]
NF-κB activator 1 (1 μM for 48 h). Staining for aging-related β-galactosidase.
NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]
Cell proliferation assays of MGLL-overexpressing stable cells, docetaxel (10 nM), and NF-κB activator 1 (1 μM, 48 h) treated with these agents.
NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]
Immunoblotting results of MGLL overexpression stable cells treated with docetaxel (10 nM) and NF-κB activator 1 (1 μM, 48 h).
-
J Mol Cell Cardiol
Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]2025 May:202:133-143. PMID: 40122157 -
Clin Exp Immunol
Docosahexaenoic acid mitigates experimental autoimmune prostatitis by inhibiting Th17 cell differentiation via the PPARγ/NF-κB/IL-17A pathway. [Abstract]2025 Jan 21;219(1):uxaf055. PMID: 40887935 -
J Immunol
2025 Jun 28:vkaf125. PMID: 40580518 -
Anim Reprod Sci
HSP72 alleviates heat stress-induced oxidative damage in boar Sertoli cells through modulating the AGE-RAGE/NOX4/NF-κB axis. [Abstract]2026 Jun:289:108144. PMID: 41740418 -
Int J Med Sci
Artemisia argyi-enhanced Mesenchymal Stem Cell Exosomes Alleviates Inflammation in C28/I2 Chondrocytes by inhibiting NF-κB. [Abstract]2026 Feb 18;23(3):1092-1104. PMID: 41799761 -
J Cancer
ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway. [Abstract]2025 Jan 1;16(3):1008-1019. PMID: 39781347 -
Behav Brain Res
2024 Mar 12:461:114837. PMID: 38145872 -
Thromb J
Liquiritin mitigates lower extremity deep vein thrombosis by inhibiting inflammation and oxidative stress via the NF-κB signaling pathway. [Abstract]2025 May 20;23(1):51. PMID: 40394684
Solvent & Solubility
DMSO : 100 mg/mL (318.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (6.62 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (6.62 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1814 mL | 15.9069 mL | 31.8137 mL | 79.5343 mL |
| 5 mM | 0.6363 mL | 3.1814 mL | 6.3627 mL | 15.9069 mL | |
| 10 mM | 0.3181 mL | 1.5907 mL | 3.1814 mL | 7.9534 mL | |
| 15 mM | 0.2121 mL | 1.0605 mL | 2.1209 mL | 5.3023 mL | |
| 20 mM | 0.1591 mL | 0.7953 mL | 1.5907 mL | 3.9767 mL | |
| 25 mM | 0.1273 mL | 0.6363 mL | 1.2725 mL | 3.1814 mL | |
| 30 mM | 0.1060 mL | 0.5302 mL | 1.0605 mL | 2.6511 mL | |
| 40 mM | 0.0795 mL | 0.3977 mL | 0.7953 mL | 1.9884 mL | |
| 50 mM | 0.0636 mL | 0.3181 mL | 0.6363 mL | 1.5907 mL | |
| 60 mM | 0.0530 mL | 0.2651 mL | 0.5302 mL | 1.3256 mL | |
| 80 mM | 0.0398 mL | 0.1988 mL | 0.3977 mL | 0.9942 mL | |
| 100 mM | 0.0318 mL | 0.1591 mL | 0.3181 mL | 0.7953 mL |
Powered by Bioz